Arbutus Biopharma Corp Operating Income
Arbutus Biopharma Corp (ABUS) reported Operating Income of -$5.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-12
CAD
| Period end | Operating Income (Loss) 12 month |
|---|---|
| 2012-12-31 | -12.92M CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | -10.54M CAD 20-F · filed 2013-03-27 |
| 2010-12-31 | -12.52M CAD 20-F · filed 2013-03-27 |
| 2009-12-31 | -8.48M CAD 20-F · filed 2012-03-27 |
USD
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$5.96M 10-Q · filed 2026-08-12 | $162.94M 10-Q · filed 2026-08-12 | $157.65M derived: sum of 3 quarters · filed 2026-08-12 | $149.00M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $168.91M 10-Q · filed 2026-05-13 | $163.62M derived: sum of 2 quarters · filed 2026-05-13 | $154.96M derived: sum of 3 quarters · filed 2026-05-13 | $156.45M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | -$5.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$13.95M derived: sum of 2 quarters · filed 2026-03-23 | -$12.46M derived: sum of 3 quarters · filed 2026-08-12 | -$38.16M 10-K · filed 2026-03-23 | ||||
| 2025-09-30 | -$8.66M 10-Q · filed 2025-11-13 | -$7.17M derived: sum of 2 quarters · filed 2026-08-12 | -$32.87M 10-Q · filed 2025-11-13 | -$46.80M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $1.49M 10-Q · filed 2026-08-12 | -$24.21M 10-Q · filed 2026-08-12 | -$38.14M derived: sum of 3 quarters · filed 2026-08-12 | -$59.58M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | -$25.70M 10-Q · filed 2026-05-13 | -$39.63M derived: sum of 2 quarters · filed 2026-05-13 | -$61.07M derived: sum of 3 quarters · filed 2026-05-13 | -$82.66M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | -$13.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$35.37M derived: sum of 2 quarters · filed 2026-03-23 | -$56.96M derived: sum of 3 quarters · filed 2026-03-23 | -$76.32M 10-K · filed 2026-03-23 | ||||
| 2024-09-30 | -$21.44M 10-Q · filed 2025-11-13 | -$43.02M derived: sum of 2 quarters · filed 2025-11-13 | -$62.39M 10-Q · filed 2025-11-13 | -$83.13M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$21.58M 10-Q · filed 2025-08-06 | -$40.95M 10-Q · filed 2025-08-06 | -$61.69M derived: sum of 3 quarters · filed 2025-08-06 | -$83.25M derived: sum of 4 quarters · filed 2025-08-06 | ||||
| 2024-03-31 | -$19.36M 10-Q · filed 2025-05-14 | -$40.11M derived: sum of 2 quarters · filed 2025-05-14 | -$61.67M derived: sum of 3 quarters · filed 2025-05-14 | -$80.05M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | -$20.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$42.30M derived: sum of 2 quarters · filed 2025-03-27 | -$60.69M derived: sum of 3 quarters · filed 2025-03-27 | -$78.10M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | -$21.56M 10-Q · filed 2024-11-06 | -$39.94M derived: sum of 2 quarters · filed 2024-11-06 | -$57.36M 10-Q · filed 2024-11-06 | -$79.92M derived: sum of 4 quarters · filed 2024-11-06 | ||||
| 2023-06-30 | -$18.39M 10-Q · filed 2024-08-08 | -$35.80M 10-Q · filed 2024-08-08 | -$58.36M derived: sum of 3 quarters · filed 2024-08-08 | -$76.17M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | -$17.41M 10-Q · filed 2024-05-02 | -$39.98M derived: sum of 2 quarters · filed 2024-05-02 | -$57.79M derived: sum of 3 quarters · filed 2024-05-02 | -$71.89M derived: sum of 4 quarters · filed 2024-05-02 | ||||
| 2022-12-31 | -$22.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$40.37M derived: sum of 2 quarters · filed 2024-03-05 | -$54.48M derived: sum of 3 quarters · filed 2024-03-05 | -$65.46M 10-K · filed 2024-03-05 | ||||
| 2022-09-30 | -$17.81M 10-Q · filed 2023-11-07 | -$31.92M derived: sum of 2 quarters · filed 2023-11-07 | -$42.89M 10-Q · filed 2023-11-07 | -$63.69M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | -$14.11M 10-Q · filed 2023-08-03 | -$25.08M 10-Q · filed 2023-08-03 | -$45.88M derived: sum of 3 quarters · filed 2023-08-03 | -$64.29M derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2022-03-31 | -$10.97M 10-Q · filed 2023-05-04 | -$31.77M derived: sum of 2 quarters · filed 2023-05-04 | -$50.18M derived: sum of 3 quarters · filed 2023-05-04 | -$68.82M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2021-12-31 | -$20.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$39.20M derived: sum of 2 quarters · filed 2023-03-02 | -$57.85M derived: sum of 3 quarters · filed 2023-03-02 | -$73.52M 10-K · filed 2023-03-02 | ||||
| 2021-09-30 | -$18.41M 10-Q · filed 2022-11-09 | -$37.05M derived: sum of 2 quarters · filed 2022-11-09 | -$52.73M 10-Q · filed 2022-11-09 | -$69.03M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | -$18.64M 10-Q · filed 2022-08-04 | -$34.32M 10-Q · filed 2022-08-04 | -$50.62M derived: sum of 3 quarters · filed 2022-08-04 | -$65.84M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | -$15.68M 10-Q · filed 2022-05-05 | -$31.98M derived: sum of 2 quarters · filed 2022-05-05 | -$47.19M derived: sum of 3 quarters · filed 2022-05-05 | -$60.34M derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | -$16.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$31.52M derived: sum of 2 quarters · filed 2022-03-03 | -$44.66M derived: sum of 3 quarters · filed 2022-03-03 | -$57.81M 10-K · filed 2022-03-03 | ||||
| 2020-09-30 | -$15.22M 10-Q · filed 2021-11-04 | -$28.36M derived: sum of 2 quarters · filed 2021-11-04 | -$41.51M 10-Q · filed 2021-11-04 | -$54.59M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-06-30 | -$13.14M 10-Q · filed 2021-08-05 | -$26.29M 10-Q · filed 2021-08-05 | -$39.38M derived: sum of 3 quarters · filed 2021-08-05 | -$130.40M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | -$13.15M 10-Q · filed 2021-05-05 | -$26.23M derived: sum of 2 quarters · filed 2021-05-05 | -$117.26M derived: sum of 3 quarters · filed 2021-05-05 | -$137.90M derived: sum of 4 quarters · filed 2021-05-05 | ||||
| 2019-12-31 | -$13.09M 10-K · filed 2020-03-05 | -$104.11M derived: sum of 2 quarters · filed 2020-11-05 | -$124.76M derived: sum of 3 quarters · filed 2020-11-05 | -$143.90M 10-K · filed 2021-03-04 | -$144.07M 10-K · filed 2020-03-05 | |||
| 2019-09-30 | -$91.03M 10-Q · filed 2020-11-05 | -$91.40M 10-Q · filed 2019-11-06 | -$111.67M derived: sum of 2 quarters · filed 2020-11-05 | -$130.87M 10-Q · filed 2020-11-05 | -$130.99M 10-Q · filed 2019-11-06 | -$147.77M derived: sum of 4 quarters · filed 2020-11-05 | ||
| 2019-06-30 | -$20.64M 10-Q · filed 2020-08-07 | -$20.52M 10-Q · filed 2019-08-05 | -$39.84M 10-Q · filed 2020-08-07 | -$39.59M 10-Q · filed 2019-08-05 | -$56.74M derived: sum of 3 quarters · filed 2020-08-07 | -$89.17M derived: sum of 4 quarters · filed 2020-08-07 | ||
| 2019-03-31 | -$19.20M 10-Q · filed 2020-05-11 | -$19.07M 10-Q · filed 2019-05-06 | -$36.10M derived: sum of 2 quarters · filed 2020-05-11 | -$68.53M derived: sum of 3 quarters · filed 2020-05-11 | -$90.57M derived: sum of 4 quarters · filed 2020-05-11 | |||
| 2018-12-31 | -$16.90M 10-K · filed 2020-03-05 | -$49.33M derived: sum of 2 quarters · filed 2020-03-05 | -$71.38M derived: sum of 3 quarters · filed 2020-03-05 | -$89.78M 10-K · filed 2020-03-05 | ||||
| 2018-09-30 | -$32.43M 10-Q · filed 2019-11-06 | -$54.47M derived: sum of 2 quarters · filed 2020-03-05 | -$32.43M 10-K · filed 2020-03-05 | -$72.88M 10-Q · filed 2018-11-07 | -$133.13M derived: sum of 4 quarters · filed 2020-03-05 | |||
| 2018-06-30 | -$22.05M 10-K · filed 2020-03-05 | -$40.45M 10-Q · filed 2019-08-05 | -$100.70M derived: sum of 3 quarters · filed 2020-03-05 | -$113.60M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2018-03-31 | -$18.41M 10-K · filed 2020-03-05 | -$78.65M derived: sum of 2 quarters · filed 2020-03-05 | -$91.55M derived: sum of 3 quarters · filed 2020-03-05 | -$111.04M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2017-12-31 | -$60.25M 10-K · filed 2019-03-07 | -$73.15M derived: sum of 2 quarters · filed 2019-03-07 | -$92.63M derived: sum of 3 quarters · filed 2019-03-07 | -$110.93M 10-K · filed 2019-03-07 | ||||
| 2017-09-30 | -$12.90M 10-K · filed 2019-03-07 | -$32.38M derived: sum of 2 quarters · filed 2019-03-07 | -$50.68M 10-Q · filed 2018-11-07 | -$308.12M derived: sum of 4 quarters · filed 2019-03-07 | ||||
| 2017-06-30 | -$19.48M 10-K · filed 2019-03-07 | -$37.78M 10-Q · filed 2018-08-03 | -$295.22M derived: sum of 3 quarters · filed 2019-03-07 | -$314.20M derived: sum of 4 quarters · filed 2019-03-07 | ||||
| 2017-03-31 | -$18.30M 10-K · filed 2019-03-07 | -$275.74M derived: sum of 2 quarters · filed 2019-03-07 | -$294.71M derived: sum of 3 quarters · filed 2019-03-07 | -$489.96M derived: sum of 4 quarters · filed 2019-03-07 | ||||
| 2016-12-31 | -$257.44M 10-K · filed 2018-03-16 | -$276.41M derived: sum of 2 quarters · filed 2018-03-16 | -$471.66M derived: sum of 3 quarters · filed 2018-03-16 | -$491.64M 10-K · filed 2018-03-16 | ||||
| 2016-09-30 | -$18.98M 10-K · filed 2018-03-16 | -$214.22M derived: sum of 2 quarters · filed 2018-03-16 | -$234.20M 10-Q · filed 2017-11-02 | -$245.96M derived: sum of 4 quarters · filed 2018-03-16 | ||||
| 2016-06-30 | -$195.25M 10-K · filed 2018-03-16 | -$215.22M 10-Q · filed 2017-08-03 | -$226.98M derived: sum of 3 quarters · filed 2018-03-16 | -$285.12M derived: sum of 4 quarters · filed 2018-03-16 | ||||
| 2016-03-31 | -$19.98M 10-K · filed 2018-03-16 | -$31.73M derived: sum of 2 quarters · filed 2018-03-16 | -$89.87M derived: sum of 3 quarters · filed 2018-03-16 | -$104.29M derived: sum of 4 quarters · filed 2018-03-16 | ||||
| 2015-12-31 | -$11.76M 10-K · filed 2017-03-22 | -$69.90M derived: sum of 2 quarters · filed 2017-03-22 | -$84.32M derived: sum of 3 quarters · filed 2017-03-22 | -$103.92M 10-K · filed 2018-03-16 | -$102.32M 10-K · filed 2016-03-09 | |||
| 2015-09-30 | -$58.14M 10-K · filed 2017-03-22 | -$72.56M derived: sum of 2 quarters · filed 2017-03-22 | -$90.56M 10-Q · filed 2016-11-03 | -$101.31M derived: sum of 4 quarters · filed 2017-03-22 | ||||
| 2015-06-30 | -$14.42M 10-K · filed 2017-03-22 | -$32.43M 10-Q · filed 2016-08-04 | -$43.17M derived: sum of 3 quarters · filed 2017-03-22 | -$50.02M derived: sum of 4 quarters · filed 2017-03-22 | ||||
| 2015-03-31 | -$18.01M 10-K · filed 2017-03-22 | -$28.75M derived: sum of 2 quarters · filed 2017-03-22 | -$35.60M derived: sum of 3 quarters · filed 2017-03-22 | -$45.02M derived: sum of 4 quarters · filed 2017-03-22 | ||||
| 2014-12-31 | -$10.75M 10-K · filed 2016-03-09 | -$17.59M derived: sum of 2 quarters · filed 2016-03-09 | -$27.01M derived: sum of 3 quarters · filed 2016-03-09 | -$33.43M 10-K · filed 2017-03-22 | -$32.97M 10-K · filed 2015-03-13 | |||
| 2014-09-30 | -$6.84M 10-K · filed 2016-03-09 | -$16.27M derived: sum of 2 quarters · filed 2016-03-09 | -$22.23M 10-Q · filed 2015-11-05 | -$24.66M derived: sum of 4 quarters · filed 2016-03-09 | ||||
| 2014-06-30 | -$9.42M 10-K · filed 2016-03-09 | -$15.38M 10-Q · filed 2015-08-07 | -$17.82M derived: sum of 3 quarters · filed 2016-03-09 | -$21.47M derived: sum of 4 quarters · filed 2016-03-09 | ||||
| 2014-03-31 | -$5.96M 10-K · filed 2016-03-09 | -$8.39M derived: sum of 2 quarters · filed 2016-03-09 | -$12.04M derived: sum of 3 quarters · filed 2016-03-09 | -$15.12M derived: sum of 4 quarters · filed 2016-03-09 | ||||
| 2013-12-31 | -$2.44M 10-K · filed 2015-03-13 | -$6.09M derived: sum of 2 quarters · filed 2015-03-13 | -$9.16M derived: sum of 3 quarters · filed 2015-03-13 | -$12.15M 10-K · filed 2016-03-09 | -$12.15M 6-K · filed 2014-03-06 | |||
| 2013-09-30 | -$3.65M 10-K · filed 2015-03-13 | -$3.65M 10-Q · filed 2014-11-07 | -$6.72M derived: sum of 2 quarters · filed 2015-03-13 | -$9.72M 10-Q · filed 2014-11-07 | ||||
| 2013-06-30 | -$3.07M 10-K · filed 2015-03-13 | -$6.07M 10-Q · filed 2014-08-14 | ||||||
| 2013-03-31 | -$2.99M 10-K · filed 2015-03-13 | |||||||
| 2012-12-31 | -$12.95M 10-K · filed 2015-03-13 | -$12.94M 6-K · filed 2014-03-06 | ||||||
| 2011-12-31 | -$10.69M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |